Immunservice Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 6

Immunservice General Information

Description

Developer of immune hormones designed to assist in the treatment of cancers, viral diseases and allergies. The company develops natural biomimetic interleukin drugs, which prevent patients with lung tumors from suffocating, rejuvenate the immune system and eliminate papillomavirus tumors, enabling healthcare professionals to provide relief with effective outcomes for the target patients.

Contact Information

Website
www.immunservice.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Christoph-Probst-Weg 4
  • 20251 Hamburg
  • Germany
+49 040
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • Christoph-Probst-Weg 4
  • 20251 Hamburg
  • Germany
+49 040

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunservice Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 05-Dec-2019 Completed Generating Revenue
3. Later Stage VC (Series C) 18-Feb-2015 Completed Generating Revenue
2. Later Stage VC 28-Jun-2014 Completed Startup
1. Seed Round 21-Jan-2008 Completed Startup
To view Immunservice’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Immunservice Patents

  • 7

    Total Documents Applications and Grants

  • Total Patents Families

  • 5

    Granted

  • Pending

  • Expiring in next 12 mo

Immunservice Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
DE-102010019614-A1 Puncture needle cover with a microneedle array Inactive 06-May-2010
EP-2384781-A1 Puncture needle cover with a microneedle array Inactive 06-May-2010
ES-2565486-T3 Interleukin-2 or interferon-alpha for use in the treatment of nicotine or food addiction Active 28-Jan-2010
US-20130028861-A1 Cytokines for the treatment of addictions Active 28-Jan-2010
US-9028808-B2 Methods for treating nicotine addiction and reducing food consumption Active 28-Jan-2010 A61K38/20
To view Immunservice’s complete patent history, request access »

Immunservice Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunservice Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
BPO Capital (Hamburg) Venture Capital Minority
Angel (individual) Minority
Angel (individual) Minority
Angel (individual) Minority
Hubertus Wald Foundation Not-For-Profit Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

Immunservice FAQs

  • When was Immunservice founded?

    Immunservice was founded in 2006.

  • Where is Immunservice headquartered?

    Immunservice is headquartered in Hamburg, Germany.

  • What is the size of Immunservice?

    Immunservice has 2 total employees.

  • What industry is Immunservice in?

    Immunservice’s primary industry is Drug Discovery.

  • Is Immunservice a private or public company?

    Immunservice is a Private company.

  • What is Immunservice’s current revenue?

    The current revenue for Immunservice is .

  • Who are Immunservice’s investors?

    BPO Capital (Hamburg), , , , and Hubertus Wald Foundation are 5 of 6 investors who have invested in Immunservice.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »